StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) stock

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.87−0.34 (-3.33%)

Close on Nov 17, 2026Market cap $676.84MP/E –Yield –

QuidelOrtho ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

QuidelOrtho's ebitda for the twelve months ending Sep 27, 2026 was $334.30M. For fiscal 2025 it was -$477.20M. The highest annual figure on record is $1.13B in fiscal 2022.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 28, 2025-$477.20M–
FY2024Dec 29, 2024-$1.51B-352.8%
FY2023Dec 31, 2023$596.30M-47.1%
FY2022Jan 1, 2023$1.13B+17.6%
FY2021Jan 2, 2022$958.70M-13.6%
FY2020Jan 3, 2021$1.11B–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 27, 2026$112.10M–
Q2 FY2026Jun 28, 2026$94.90M–
Q1 FY2026Mar 29, 2026$81.10M-41.9%
Q4 FY2025Dec 28, 2025$46.20M+419.1%
Q3 FY2025Sep 28, 2025-$592.70M-562.7%
Q2 FY2025Jun 29, 2025-$70.40M–
Q1 FY2025Mar 30, 2025$139.70M–
Q4 FY2024Dec 29, 2024$8.90M-94.3%
Q3 FY2024Sep 29, 2024$128.10M-8.1%
Q2 FY2024Jun 30, 2024-$1.40M-101.6%
Q1 FY2024Mar 31, 2024-$1.64B-868.5%
Q4 FY2023Dec 31, 2023$155.50M-23.4%
Q3 FY2023Oct 1, 2023$139.40M-13.4%
Q2 FY2023Jul 2, 2023$87.60M-31.1%
Q1 FY2023Apr 2, 2023$213.80M-66.4%
Q4 FY2022Jan 1, 2023$203.10M-48.2%
Q3 FY2022Oct 2, 2022$161.00M-45.3%
Q2 FY2022Jul 3, 2022$127.20M+257.3%
Q1 FY2022Apr 3, 2022$636.00M–
Q4 FY2021Jan 2, 2022$392.10M–
Q3 FY2021Oct 3, 2021$294.50M–
Q2 FY2021Jul 4, 2021$35.60M–

More QuidelOrtho figures

See a number that looks wrong?